ESLT vs. VRNA

Last updated Jun 19, 2026

ESLT (Elbit Systems Ltd) and VRNA (Verona Pharma plc) are both stocks. ESLT operates in Aerospace & Defense (Industrials), while VRNA operates in Biotechnology (Healthcare). At a 0.08 correlation, their price movements are largely independent.

Performance

ESLT vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Elbit Systems Ltd (ESLT) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

ESLT

• 1D: -4.09%
• 1M: 2.23%
• YTD: 36.59%
• 6M: 46.01%
• 1Y: 80.80%
• 3Y*: 57.62%
• 5Y*: 44.45%
• 10Y*: 25.28%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ESLT vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ESLT Elbit Systems Ltd	36.59%	125.14%	22.17%	31.30%	-4.82%	34.77%	-14.56%	37.62%	-13.22%	12.78%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between ESLT and VRNA is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.05
Correlation (3Y) Calculated over the trailing 3-year period	0.11
Correlation (5Y) Calculated over the trailing 5-year period	0.08
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.08

Fundamentals

Market Cap ESLT : $37.93B VRNA : $9.72B
EPS ESLT : $12.36 VRNA : -$0.69
PS Ratio ESLT : 4.55 VRNA : 57.97
PB Ratio ESLT : 8.90 VRNA : 34.92
Total Revenue (TTM) ESLT : $8.23B VRNA : $167.65M
Gross Profit (TTM) ESLT : $2.03B VRNA : $159.52M
EBITDA (TTM) ESLT : $861.06M VRNA : -$40.86M

Return for Risk

ESLT vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ESLT

ESLT Risk / Return Rank: 85
ESLT Sharpe Ratio Rank: 87
ESLT Sortino Ratio Rank: 87
ESLT Omega Ratio Rank: 84
ESLT Calmar Ratio Rank: 84
ESLT Martin Ratio Rank: 85

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ESLT vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Elbit Systems Ltd (ESLT) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ESLT	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	1.84	—	—
Sortino ratio: Return per unit of downside risk	2.75	—	—
Omega ratio: Gain probability vs. loss probability	1.33	—	—
Calmar ratio: Return relative to maximum drawdown	3.13	—	—
Martin ratio: Return relative to average drawdown	8.39	—	—

Drawdowns

Drawdown Indicators

	ESLT	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-53.79%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-25.98%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-25.98%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-32.89%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-32.89%	—	—
Current Drawdown Current decline from peak	-22.21%	—	—
Average Drawdown Average peak-to-trough decline	-13.92%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	9.66%	—	—

Volatility

Volatility by Period

	ESLT	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	20.55%	—	—
Volatility (6M) Calculated over the trailing 6-month period	36.50%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	44.24%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.72%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	29.48%	—	—

Dividends

ESLT vs. VRNA - Dividend Comparison

ESLT's dividend yield for the trailing twelve months is around 0.39%, while VRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ESLT Elbit Systems Ltd	0.39%	0.47%	0.77%	0.94%	1.22%	1.03%	1.28%	1.14%	1.54%	1.32%	1.57%	1.63%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

ESLT vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Elbit Systems Ltd and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ESLT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Elbit Systems Ltd reported a gross profit of 552.06M and revenue of 2.19B. Therefore, the gross margin over that period was 25.2%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

ESLT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Elbit Systems Ltd reported an operating income of 205.13M and revenue of 2.19B, resulting in an operating margin of 9.4%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

ESLT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Elbit Systems Ltd reported a net income of 160.79M and revenue of 2.19B, resulting in a net margin of 7.4%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both ESLT and VRNA in my portfolio?

ESLT and VRNA have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.